TECregen Raises CHF 10M In Seed Funding

The funding round was led by Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.

TECregen plans to use the funding to accelerate development of its thymopoietic biologics, which are designed to rejuvenate thymic epithelial cells (TECs), restore immune function and enhance overall immune resilience.

Read Also - Legaltech Alice Raises €1M To Enhance Reliable Legal Workflows

The company’s approach targets conditions caused by impaired T-cell responses focusing on revitalizing and expanding TECs to replenish T cells and achieve long-lasting improvements in immune function.

“I am honored to join TECregen’s Board at such a pivotal time for the company,” said Dr. Bo Rode Hansen, Chairman of TECregen. “The team’s pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune ageing and related disease. I look forward to working with the management team and our investors to accelerate the development and delivery of these transformative therapies to patients who need them most.”

By building a pipeline of differentiated thymopoietic biologics, TECregen aims to support immune recovery after transplantation or cytotoxic therapy, promote overall immune health, and strengthen immune surveillance against cancer.

Additionally, TECregen has appointed Dr. Bo Rode Hansen, Ph.D., MBA, as Chairman of the Board of Directors.

About TECregen

TECregen AG is advancing immuno-rejuvenation by developing therapies to regenerate the thymus. Focusing on revitalizing thymic epithelial cells (TECs) the company aims to restore T-cell function support immune recovery after transplantation or therapy, promote overall immune health, and enhance cancer immune surveillance through its pipeline of thymopoietic biologics.